UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 47,310 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 486,769 shares of the biopharmaceutical company’s stock after selling 47,310 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.16% of Amicus Therapeutics worth $5,199,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Diversified Trust Co boosted its holdings in shares of Amicus Therapeutics by 7.8% during the 2nd quarter. Diversified Trust Co now owns 71,803 shares of the biopharmaceutical company’s stock valued at $712,000 after buying an additional 5,170 shares in the last quarter. Wedge Capital Management L L P NC grew its holdings in Amicus Therapeutics by 12.3% in the second quarter. Wedge Capital Management L L P NC now owns 233,049 shares of the biopharmaceutical company’s stock worth $2,312,000 after purchasing an additional 25,564 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Amicus Therapeutics during the second quarter valued at approximately $8,386,000. AlphaCentric Advisors LLC lifted its holdings in shares of Amicus Therapeutics by 15.7% during the second quarter. AlphaCentric Advisors LLC now owns 202,500 shares of the biopharmaceutical company’s stock valued at $2,009,000 after purchasing an additional 27,500 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Amicus Therapeutics by 7.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,245,115 shares of the biopharmaceutical company’s stock worth $12,352,000 after purchasing an additional 82,065 shares in the last quarter.

Amicus Therapeutics Trading Up 0.3 %

Shares of FOLD opened at $10.16 on Thursday. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The company’s fifty day moving average is $10.55 and its 200 day moving average is $10.61. The stock has a market capitalization of $3.04 billion, a PE ratio of -29.88 and a beta of 0.60.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders have sold 30,401 shares of company stock worth $339,363. 2.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on FOLD. Cantor Fitzgerald lifted their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Bank of America boosted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Guggenheim lifted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Morgan Stanley decreased their target price on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Finally, Jefferies Financial Group began coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $17.63.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.